Cart
sales@molnova.com
SU-9516 (b)
CAS No. 666837-93-0
SU-9516 (b)( —— )
Catalog No. M22990 CAS No. 666837-93-0
SU9516 is a selectively potent ATP-competitive inhibitor of CDKs.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 120 | In Stock |
|
| 10MG | 156 | In Stock |
|
| 25MG | 234 | In Stock |
|
| 50MG | 304 | In Stock |
|
| 100MG | 396 | In Stock |
|
| 500MG | 888 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSU-9516 (b)
-
NoteResearch use only, not for human use.
-
Brief DescriptionSU9516 is a selectively potent ATP-competitive inhibitor of CDKs.
-
DescriptionSU9516 is a selectively potent ATP-competitive inhibitor of CDKs.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number666837-93-0
-
Formula Weight241.24
-
Molecular FormulaC13H11N3O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C1NC2=C(C=C(OC)C=C2)C1=CC3=CN=CN3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Collins I , Garrett M D . Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors[J]. Current Opinion in Pharmacology, 2005, 5(4):366-373.
molnova catalog
related products
-
CDK9-IN-10
CDK9-IN-10 is a potent CDK9 inhibitor and the ligand for the PROTAC CDK9 degrader-2.
-
VMY-1-103
A novel dansylated analog of purvalanol B, and a CDK inhibitor that inhibits cell cycle progression and proliferation in prostate and breast cancer cells more effectively than purvalanol B.
-
CDK7 and 9 inhibitor...
A potent, selective transcriptional CDK inhibitor with Ki of 2.3 and 0.38 nM for CDK7 and CDK9, respectively; displays >30-fold selectivity over CDK1/2/4, inhibits VEGFR2 with IC50 of 180 nM in a panel of non-CDK kinases.
